NO20072005L - Nye heterocykliske amider - Google Patents

Nye heterocykliske amider

Info

Publication number
NO20072005L
NO20072005L NO20072005A NO20072005A NO20072005L NO 20072005 L NO20072005 L NO 20072005L NO 20072005 A NO20072005 A NO 20072005A NO 20072005 A NO20072005 A NO 20072005A NO 20072005 L NO20072005 L NO 20072005L
Authority
NO
Norway
Prior art keywords
new heterocyclic
heterocyclic amides
compounds
preparation
salts
Prior art date
Application number
NO20072005A
Other languages
English (en)
Norwegian (no)
Inventor
Yevgeni Besidski
Inger Kers
Martin Nylof
Andis Slaitas
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20072005L publication Critical patent/NO20072005L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/08—Radicals containing only hydrogen and carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
NO20072005A 2004-09-21 2007-04-19 Nye heterocykliske amider NO20072005L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0402284A SE0402284D0 (sv) 2004-09-21 2004-09-21 New heterocyclic amides
PCT/SE2005/001364 WO2006033620A1 (en) 2004-09-21 2005-09-19 New heterocyclic amides

Publications (1)

Publication Number Publication Date
NO20072005L true NO20072005L (no) 2007-06-15

Family

ID=33308795

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20072005A NO20072005L (no) 2004-09-21 2007-04-19 Nye heterocykliske amider

Country Status (14)

Country Link
US (1) US20080015222A1 (sv)
EP (1) EP1797067A1 (sv)
JP (1) JP2008513443A (sv)
KR (1) KR20070056104A (sv)
CN (1) CN101023071A (sv)
AU (1) AU2005285656A1 (sv)
BR (1) BRPI0515429A (sv)
CA (1) CA2577818A1 (sv)
IL (1) IL181765A0 (sv)
MX (1) MX2007003119A (sv)
NO (1) NO20072005L (sv)
SE (1) SE0402284D0 (sv)
WO (1) WO2006033620A1 (sv)
ZA (1) ZA200702050B (sv)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0301446D0 (sv) * 2003-05-16 2003-05-16 Astrazeneca Ab New Compounds
WO2006034418A2 (en) * 2004-09-21 2006-03-30 Athersys, Inc. Benzimidazole acetic acids exhibiting crth2 receptor antagonism and uses thereof
WO2007054480A1 (en) 2005-11-08 2007-05-18 N.V. Organon 2-(benzimidazol-1-yl)-acetamide biaryl derivatives and their use as inhibitors of the trpv1 receptor
UY30048A1 (es) * 2005-12-23 2007-07-31 Astrazeneca Ab Derivados sustituidos de la n,2-(1h-benzimidazol-1-il) acetamida, composiciones farmacéuticas conteniéndolos, procesos de preparación y aplicaciones
TWI433839B (zh) * 2006-08-11 2014-04-11 Neomed Inst 新穎的苯并咪唑衍生物290
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
WO2011092293A2 (en) 2010-02-01 2011-08-04 Novartis Ag Cyclohexyl amide derivatives as crf receptor antagonists
AR080055A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de pirazolo-[5,1-b]-oxazol como antagonistas de los receptores de crf -1
JP5748777B2 (ja) 2010-02-02 2015-07-15 ノバルティス アーゲー Ｃｒｆ受容体アンタゴニストとしてのシクロヘキシルアミド誘導体
WO2013078413A1 (en) * 2011-11-22 2013-05-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Modulators of lipid storage
JP2018052817A (ja) * 2015-01-21 2018-04-05 大日本住友製薬株式会社 新規ベンズイミダゾール誘導体およびその医薬用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1036004B (it) * 1968-05-21 1979-10-30 Abc Ist Biolog Chem Spa Acidt 3 indolil adetoidrossamici
JPH06759B2 (ja) * 1989-09-22 1994-01-05 ファイザー製薬株式会社 新規なベンゾイミダゾール化合物
US6534651B2 (en) * 2000-04-06 2003-03-18 Inotek Pharmaceuticals Corp. 7-Substituted isoindolinone inhibitors of inflammation and reperfusion injury and methods of use thereof
AU2001259707A1 (en) * 2000-06-14 2001-12-24 Warner Lambert Company 6,5-fused bicyclic heterocycles
GB0031315D0 (en) * 2000-12-21 2001-02-07 Glaxo Group Ltd Indole derivatives
US20030158188A1 (en) * 2002-02-20 2003-08-21 Chih-Hung Lee Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
CA2501539A1 (en) * 2002-10-17 2004-04-29 Amgen Inc. Benzimidazole derivatives and their use as vanilloid receptor ligands
SE0301446D0 (sv) * 2003-05-16 2003-05-16 Astrazeneca Ab New Compounds

Also Published As

Publication number Publication date
KR20070056104A (ko) 2007-05-31
BRPI0515429A (pt) 2008-07-22
AU2005285656A1 (en) 2006-03-30
CN101023071A (zh) 2007-08-22
ZA200702050B (en) 2008-09-25
WO2006033620A1 (en) 2006-03-30
EP1797067A1 (en) 2007-06-20
US20080015222A1 (en) 2008-01-17
MX2007003119A (es) 2007-05-24
JP2008513443A (ja) 2008-05-01
IL181765A0 (en) 2007-07-04
SE0402284D0 (sv) 2004-09-21
CA2577818A1 (en) 2006-03-30

Similar Documents

Publication Publication Date Title
NO20072005L (no) Nye heterocykliske amider
NO20055977L (no) Nye benzimidazolderivater
NO20063468L (no) Triazolforbindelser og deres anvendelse som metabotrofe glutamatreseptorantagonister
NO20060001L (no) Nye P2X7-reseptorantagonister og deres anvendelse
NO20063469L (no) Polyeheterosykliske forbindelser og deres anvendelse som metabotrofe glutamat reseptorantagonister
NO20071593L (no) Pyrimidinderivater
NO20083246L (no) Nye benzimidazolderivater som vanilloid-reseptor 1 (VRL) inhibitorer
NO20083427L (no) Cystoksiske midler omfattende nye tomaymycinderivater og deres terapeutiske anvendelse
NO20063599L (no) Ytterligere heterosykliske forbindelser og deres anvendelse som metabotrofiske glutamatreseptorantagonister
NO20090628L (no) Pyridizinon derivativater
NO20070224L (no) 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav
NO20053201L (no) Nye heterocykliske fluorglukosidderivater, legemidler inneholdende disse forbindelser og deres anvendelse.
NO20071137L (no) Nye piperidinderivater for behandling av depresjon
NO20052028L (no) Pyridinderivater som CB2 reseptor modulatorer
NO20070489L (no) 3-aminocyklopentankarboksamider som modulatorer av kjemokinreseptorer.
NO20084912L (no) Bisykliske derivater som CETP-inhibitorer
NO20071619L (no) Fremgangsmate for fremstilling av indazol forbindelse
SE0403171D0 (sv) New compounds
NO20081001L (no) Derivater av karboksamid som antagonister for muskarinisk reseptor
DK1730147T3 (da) Substituerede 1,4,8-triazaspiro[4.5]decan-2-on-forbindelser til behandling af fedme
NO20084186L (no) Nye aminer
NO20061981L (no) Arylindenopyridiner og arylindenopyridiner og deres anvendelse som adenosin A2A reseptoragonist
TW200745122A (en) New compounds I
NO20083738L (no) Sekundaere aminer som renininhibitorer
NO20062533L (no) 5-fluor, 5-klor- og cyanopyridin-2-yl-tetrazoler som ligander for den metabotrofe glutamatreseptor-5

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application